Incannex Healthcare Limited (IHL.AX)
Chart Events
Performance Outlook
| Previous Close | 0.3300 |
| Open | 0.3250 |
| Bid | 0.3050 x 19574500 |
| Ask | 0.3100 x 30420000 |
| Day's Range | 0.3050 - 0.3250 |
| 52 Week Range | 0.1850 - 0.7550 |
| Volume | |
| Avg. Volume | 3,813,271 |
| Market Cap | 397.522M |
| Beta (5Y Monthly) | 2.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0120 |
| Earnings Date | Aug 29, 2022 - Sep 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IHL.AX
Related Research
- GlobeNewswire
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors
Highlights: Highly experienced pharmaceutical executive with 20+ years at Pfizer and 10+ years at Novo NordiskSecured FDA registration and marketing approval for 12 significant new drugs in the past 10 years at Novo Nordisk in his capacity of Vice President – US Regulatory AffairsPersonal leadership of more than 15 successful US FDA Advisory Committee Meetings on behalf of Novo Nordisk and PfizerNationally recognized expert on FDA/EMA liaison interactions and US pharmaceutical advertising and pr
- Simply Wall St.
Do Institutions Own Incannex Healthcare Limited (ASX:IHL) Shares?
The big shareholder groups in Incannex Healthcare Limited ( ASX:IHL ) have power over the company. Large companies...
- PR Newswire
Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').
